A phase II open-label study of aprepitant as anti-emetic prophylaxis in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy-Reference-Cited by-同舟云学术

A phase II open-label study of aprepitant as anti-emetic prophylaxis in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy

Published:2018-10-19 Issue:6 Volume:27 Page:2295-2300
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Brandwein Joseph M.^ORCID,Seki Jack T.,Atenafu Eshetu G.,Rostom Amr,Lutynski Andrzej,Rydlewski Anna,Schimmer Aaron D.,Schuh Andre C.,Gupta Vikas,Yee Karen W. L.

Funder

Merck Canada

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00520-018-4515-4.pdf

Reference16 articles.

1. Roila F, Molassiotis A, Herrstedt J et al (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27(suppl 5):119–133

2. Geling O, Eichler HG (2005) Should 5-HT3 receptor antagonists be administered beyond 24 hours following chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23:1289–1294

3. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J (2006) Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472–4478

4. De Boer-Dennert M, de Wit R, Schmitz PI et al (1997) Patient perceptions of the side effects of chemotherapy: the influence of 5-HT antagonists. Br J Cancer 76:1055–1061

5. Hesketh PJ, Grunberg SM, Gralla RJ et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational randomized double-blind placebo controlled trial in patients receiving high-dose cisplatin—the aprepitant protocol 052 study group. J Clin Oncol 21:1–8

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physicochemical parameters and thermodynamic behavior of aprepitant/HS15 micellar system at different temperatures: Effect of electrolytes concentration;Journal of Molecular Liquids;2021-04

2. Addition of aprepitant improves acute emesis control in children and adolescents receiving induction chemotherapy for acute myeloid leukaemia: a randomised, open-label trial;BMJ Supportive & Palliative Care;2020-10-29

3. Every‐other‐day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the “Rete Ematologica Pugliese”;Cancer Medicine;2019-11-14